N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
CA 2499494 A1 · Owner: Pfizer Inc. · Inventors: Katsu, Yasuhiro; Noguchi, Hirohide; Uchida, Chikara
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides a compound of the formula (I): wherein Rl represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom etc.; R3 , represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group in R3 is substituted by at least one substituent selected from the group consisting of substituents .alpha. ; said substituents .alpha. are selected from the group consisting of aryl groups hydroxy groups, oxo groups, etc.; , said aryl groups have 6 to 10 carbon atoms; said aryl groups are unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic groups and heterocyclic moiety in heterocycliccarbonyl groups …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 8, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 8, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 8, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.